Array Technologies heads into mid-June with a striking split personality: short sellers are adding exposure at the fastest pace in months while options traders have abruptly swung from heavily defensive to near-neutral.
The short interest story is the dominant angle this week. Bears have rebuilt positions aggressively — short interest climbed nearly 10% over the past week to 19.9% of the free float, with roughly 30.4 million shares now borrowed against the stock. That follows a prior period of relative stability in the 27–28 million share range, making the June spike notable. Days to cover stand at 5.6 based on official FINRA data, meaning any sharp move higher would take almost a full trading week to unwind. The short score of 69.1, while easing slightly from a peak of 71.7 earlier this month, keeps ARRY firmly in high-conviction bearish territory — the short score rank places it in just the 3rd percentile of the universe, flagging extreme short positioning relative to peers. The borrow market, however, tells a different story about conviction. Availability is running at roughly 110% — meaning the lending pool holds about as many shares available to borrow as are currently borrowed — and cost to borrow has dropped 25% over the week to just 0.7%. Bears are piling in, but they are doing so cheaply and without constraint. That's a positioning dynamic that looks more like a crowded trade than a stressed one.
Options positioning has flipped sharply in the opposite direction. For most of the past six weeks, the put/call ratio ran close to 1.0, reflecting heavy demand for downside protection. That changed abruptly in early June — the ratio collapsed to 0.16 by mid-week before bouncing back to 0.42 on Tuesday. The PCR's 20-day mean sits at 0.41, and the current reading is barely a tenth of a standard deviation above that average, meaning the options market is essentially neutral after an extended period of defensive loading. The 52-week PCR high of 0.99 and current reading of 0.42 frame how dramatic the rotation away from put hedging has been. Shorts are adding; options hedgers are backing off. That's a genuine tension in the positioning picture.
The Street is cautiously positive, though targets sit well above where the stock is trading. The consensus leans bullish — UBS maintains Buy with an $11 target, JPMorgan holds Overweight at $10, and Citi raised its target to $12 in April. The mean price target across the analyst group is $10.27, implying roughly 31% upside to Tuesday's close of $7.86. That's not nothing, but it has to be read against a stock that has fallen 12% over the past month and 2.7% in a single session on Tuesday. Morgan Stanley's March note set an Equal-Weight target of $7, essentially flagging fair value at current levels. The bull case centres on EBITDA multiple expansion — the valuation has moved from 11x to 13x 2025 EBITDA — and on signs of revenue recovery after a period of market share loss. The bear case is more structural: margin dilution from international expansion, exposure to EPC-driven demand that can soften quickly, and limited direct customer relationships. The EV/EBITDA multiple of 9.2x has compressed slightly over the past month, consistent with the price softness. EPS surprise ranks in the 90th percentile, a quietly important detail suggesting the company has consistently outrun lowered expectations.
Institutional activity adds texture. BlackRock added nearly 5.8 million shares in the most recent reported period, building to a 19% ownership stake — the largest on the register. AXA Investment Managers entered a near-full position, adding 9.6 million shares in Q1. Wellington Management and two Vanguard vehicles also disclosed new or significantly increased positions. That's a substantial wave of institutional buying against a backdrop of rising short interest, which sets up the classic tug-of-war between long-term fundamental buyers and shorter-term tactical sellers. Insider activity in the quarter has been dominated by stock awards rather than open-market purchases, and the one cash transaction on record — the CFO selling roughly $80,000 worth of stock in March — carries minimal signal weight.
The next earnings release is pencilled in for August 5. The most recent print in May produced a muted one-day move of just -2.2%, followed by a five-day drift that was essentially flat. What to watch between now and then: whether the short rebuild continues past 20% of the float, whether the options PCR spikes back toward its defensive highs, and whether the wide gap between analyst price targets and the current share price begins to close — or whether the bears' conviction proves better-calibrated than the Street's optimism.
See the live data behind this article on ORTEX.
Open ARRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
